B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
BCAX
Bicara TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
$10.02-$0.09 (-0.89%)
At close · 2026-11-13
Current thesis
The earnings release confirmed substantial pivotal-trial enrollment and $442.3 million of cash, equivalents and marketable securities at September 30, with management projecting funding into the first half of 2029. Those resources support the mid-2027 readout without an immediate funding requirement under current plans [#SEC-8K-2026-11-09].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -18.7.
What can break
Genmab's positive Phase 3 petosemtamab results raise the bar for differentiation in overlapping first-line head-and-neck cancer patients. Genmab announcement
Momentum
1
Value
41
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $19.00 · Bear $5.50Analysis 2026-11-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-13 • Vendor: Data Vendor v1
Scores
As of 2026-11-13 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-13
Investment thesis
As of 2026-11-13
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-13. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $32.17
Why
Momentum1 · Δ7d -0.1
Value41 · Δ7d -0.0
Sentiment80 · Δ7d -18.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -18.7.
Contradictions & invalidation
- • Genmab's positive Phase 3 petosemtamab results raise the bar for differentiation in overlapping first-line head-and-neck cancer patients. Genmab announcement
- • Pivotal FORTIFI-HN01 efficacy, safety or timing could disappoint; substantial enrollment does not establish clinical benefit [#SEC-8K-2026-11-09].
- • Competition has intensified: Genmab reported positive first-line Phase 3 survival and response results in a population including HPV-negative patients.
Catalyst clock
2026-12-16
Tumor-targeted TGF-β preclinical presentation
Lead driver: Sentiment · See AI snapshot
Momentum
1
18% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-7.3
Value
41
43% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.0
Sentiment
80
39% active weight
Current posture
7d trendSoftening
Δ7d
-18.7
Δ21d
-1.4
Why this grade
Composite grade D. Momentum 1.3 / Value 40.6 / Sentiment 80.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-12. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-13
Fundamentals (TTM)
As of 2026-11-13
Market Cap
$665.2M
Beta
-
Shares Out
66.39M
P/E (TTM) · Derived
-4.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.46
Rev YoY
-
EPS YoY
+62.5%
Gross Margin
-
Op Margin
-
Net Debt
-$413.09M
Current Ratio
11.59
As of 2026-11-13 • Updated nightlySource: Internal modelMethods & Data